Introduction
Without antiretroviral therapy (ARV), most individuals infected by human immunodeficiency virus type 1 (HIV-1) experience persistent viral replication and a declining CD4+ T cell count, leading to the acquired immunodeficiency syndrome within 10 years.
So-called elite controllers (EC) spontaneously control HIV replication, with low or undetectable HIV-RNA load, strong HIV-1-specific CD8+ T cell responses, and normal CD4+ T cell counts. These individuals represent about 1% of all HIV-infected patients. Their viral load can only be detected by using ultrasensitive assays (b1 copy/ml). Viral sequencing usually reveals no consistent gene deletions or signatures associated with reduced replicative capacity. This spontaneous viral control seems to be driven by host gene polymorphisms such as the CCR5 Δ 32 deletion or specific HLA class I alleles (B*27 or B*57) (Antoni et al., 2013) , and by robust immune responses (Pereyra et al., 2008) , consistent with predominant linkage between the HLA class I locus and EC status (Xie et al., 2010) .
Here we report the complete natural history of a very rare elite controller during a 10-year period of untreated infection. The patient was a homosexual man with a history of repeated unprotected receptive anal intercourse for ten months with his first and only (HIV-1-infected) partner. He differs from elite controllers reported in other studies by his lack of a (homozygous or heterozygous) protective HLA-class I allele (Bailey et al., 2008; Mendoza et al., 2012; Buckheit et al., 2012) . We were also able to study the immunological and virological outcomes of his partner during the same period.
Case Report
A 25-year-old man was tested for HIV in November 2007, after reporting unprotected receptive anal sex with pre-ejaculatory fluid exposure from October 2006 to July 2007 with his first and only sexual partner. Both men were uncircumcised. Our case report declared that his first HIV test, in July 2006, had been negative. He was found to be HIV-1-positive by ELISA (HIV-2-and HTLV I/II-negative). HIV-1 WB showed first weak reactivity with antibodies to gp160, p55 and p25 from 2007 to 2014, then positive reactivity with antibodies to gp160, p55, gp41, p40, p24 and p18 and weak reactivity with antibodies to gp110 from three sera sampled between January and November 2015 retested simultaneously (Fig.1a) . In April 2017, HIV-1 WB remained incomplete with positive reactivity with antibodies to gp160, p55, gp41, p40, p25, p18, weak reactivity with antibodies to gp110 and no reactivity with antibodies to p68, p34 (Fig. 1a) . Dates of serological, T-cell and genotyping assays are indicated below the charts. Plasma IgA, IgG and IgM levels were normal from 2007 to 2017, ruling out impaired global antibody production.
Methods
Serum was tested with the following assays: Genscreen Ultra Ag-Ab (Bio-Rad®), Biotest (DiaSorin®), Determine HIV-1/2 (Abbott®), Vidas HIV Duo (bioMérieux®), Vitros HIV1/2 assay (OrthoDiagnostics®), Vironostika HIV Uniform II Ag/Ab (Organon Teknika®), and HIV Architect Combo (Abbott®). Discrimination between HIV-1 and HIV-2 was achieved by using the Immunocomb II HIV1/2 BiSpot (Orgenics®). HIV-1 Western blot was performed using the New Lav Blot 1 (Biorad®). The partner's genotype was analyzed with the ANRS-AC11 algorithm.
HLA sequences were read with a LABScan 200 (Luminex Technology) and computer-assisted HLA Fusion software. KIR genotyping was performed by PCR using standard primers, and internal controls (Vilches et al., 2007) .
HIV-1-specific responses were evaluated first by using an IFN-γ ELISpot assay on PBMC and lymph node (LN) cells stimulated with 18 pools of 15-mer synthetic peptides targeting Gag, Reverse Transcriptase and Nef (Samri et al., 2006) . Second multi-parametric flow cytometry was performed to further assess HIV-specific CD8 T cells by intracellular cytokine staining (ICS) of IFN-γ, IL2, TNFα and MIP1β, and CD40L expression after incubation with the HIV-1 peptide pools that had induced an IFN-γ ELISpot response (Cardinaud et al., 2011) . A CMV peptide and staphylococcal enterotoxin B (SEB) were used as positive controls. Cells were stained with anti-CD3/PB, anti-CD8/APC-CY7, anti-IFN-γ/Alexa-700, anti-TNF α/PCy7, anti-IL2/APC (BD Bioscience®) and anti-CD4/ ECD (Beckman Coulter®) ( Supplementary Fig. 1 Strategy of staining for poly-functional assays). Poly-functional NK was performed to simultaneously detect degranulation (anti-CD107a mAb, BD Biosciences) and cytokine production (intracellular expression IFN-γ (BD Biosciences) and TNF-α (E-Biosciences) (Béziat et al., 2012) .
Finally, multi-parametric analysis of CD4 and CD8 blood T cells was performed for studying activation markers (HLA-DR, CD38, CD25, CD69) and immune check points (PD-1, TIM-3, CTLA-4) combined to anti-CD3, -CD4, -CD45RA, -CD27, -CCR7, -CXCR5, and -CD32. Data were acquired with a Gallios flow cytometer and analyzed with Kaluza-1.2 software (Beckman Coulter®).
Cell-surface expression of CD107a and intracellular expression of TNF-a and IFN-g were assessed on PBMC from the case report (in November 2010 and May 2016) or his partner (in August 2011) in the absence of target (alone), and in the presence of MHC class-I negative K562 cells or CD20 + RAJI cells treated by 1 μg/mL of anti-CD20 mAb (αCD20; Rituximab, Roche), or an Isotype control (Ig Ctl). Effector and target are used at a 1/1 ratio. The values were analyzed with a Boolean gate algorithm (FlowJo; Tree Star). Data are presented as pie charts created with Pestle and Spice software. Colored arcs represent the frequencies of cells producing CD107a, TNF-α and IFN-γ. Pie fractions represent cells performing 0, 1, 2, or 3 functions simultaneously.
HIV-1 RNA was measured by an ultrasensitive assay. Total cell-associated HIV-1 DNA in collected PBMC was detected using an ultrasensitive assay (Descours et al., 2012 , Avettand-Fenoel et al., 2008 . The technics to isolate the virus from in vitro-stimulated total and CD4 + FACS-sorted T cells from blood and tissues and ultrasensitive assays have been previously described (Avettand-Fenoel et al., 2009) .
The heat-inactivated serum was tested for neutralizing activity, starting the dilutions at 1:10, using the TZM-bl assay as previously described (Bouvin-Pley et al., 2013) and MN, BX08 and NL4-3 as a highly sensitive (tier 1) indicator strains (Simek et al., 2009) .
Informed written consent for participation in this research, including genetic analysis, was obtained from both men, in accordance with French ethical requirements and the Helsinki Declaration.
Results
Until May 2017, HIV-1 RNA was strictly undetectable in blood with a routine assay (b 20 copies/ml) (Fig. 1b) and HIV-1 WB remained incomplete from November 2007 to April 2017 (middle panel) (Fig. 1a) .
Two copies of HIV-1 RNA was detected in plasma with an ultra-sensitive assay in September 2009 (detection limit b1 copy/mL), (Fig. 1b) but not in May 2015 (detection limit b1 copy/mL). Six other samples collected between February 2008 and April 2017 were assessed by ultrasensitive PCR: HIV-RNA was not detected (threshold varying between 1.1 log and 1.6 log according to the volume available) in hidden taking of antiretroviral drugs, as no drug was detected in plasma in February 2008 and September 2013.
We detected total cell-associated HIV-DNA in PBMC collected in 2008. Cell-associated HIV-DNA was detected in PBMC at 1.1 copies/ 10 6 cells in 2009 and 2 copies/10 6 cells (0.4 log) in 2015. Cell-associated HIV-DNA was detected at 1.2 copies/10 6 cells in rectal but was not detected in ileal biopsies in 2011 (Fig. 1b) . A 241-bp fragment of the integrase coding region (pol-IN) was amplified by PCR ( Fig. 3b ). Subsequent amplification attempts on the same sample and on other samples collected in 2009, with targets including highly conserved regions of the env gene (gp41), were all negative. Finally, attempts to isolate the virus from in vitro-stimulated total and CD4 + FACS-sorted T cells from blood, bone marrow, lymph nodes and rectal biopsy specimens were negative.
Given the low HIV-1-RNA and HIV-1-DNA levels and the patient's heterozygosity for the CCR5 Δ 32 haplotype, we analyzed in 2009 his CD4 + T cells' susceptibility to the following viral strains: HIVYU2b (R5-tropic), HIVNL4-3 (X4-tropic) and HIV KON , the latter being a primary isolate belonging to the same clade as his own CRF02_AG variant. Activated CD4+ T cells from blood were challenged in vitro, and p24 Gag release was monitored by ELISA. The cells were clearly susceptible to all the strains, including HIV KON (Fig. 2a) .
We then analyzed extensively his immune status. The patient was HLA-A*03 -A*31 and was homozygous for the pejorative allele B*07*07 as well as for HLA-C*07 and DQB1 06. A CD4 and CD8 T cell multi-parametric phenotypic analysis showed in 2010 and 2016 (Supplementary Table 1) Patient's NK cells from case report and partner were not constitutively activated, and showed no clonal NK-cell population. Poly-functional analysis revealed no major functional defects, in the presence of K562 targets, but in contrast, a robust capacity of antibody-dependant cell cytotoxicity (ADCC) was observed in NK cells from the case patient, at two different time-points (March 2010 and November 2016), in the presence of Raji cells treated by anti-CD20 mAb (Fig. 4) . Case report was of group B KIR haplotype (characterized by one or more of the following genes: KIR2DL5, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS5 and KIR3DS1).
We checked the putative presence of a neutralizing activity in the serum of our patient. Serum collected in November 2010 was tested first. Starting at a dilution of 1:10, no neutralizing activity towards the highly neutralization-sensitive strains MN and BX08 (tier 1) was detected. No neutralizing activity was detected in November 2015, several years later after the initial HIV diagnosis, even towards a very sensitive strain such as NL4-3, (another highly neutralization-sensitive indicator strain).
The case report had HLA-A*03 -A*31, with both HLA-B*07 and HLA-C*07 homozygous alleles, and was homozygous for DQB1 06 (Supplementary Table 1 ) and had a heterozygous CCR5Δ32 haplotype.
We monitored the patient's only sexual partner from October 2006 to July 2007 who had developed a highly symptomatic primary HIV-1 infection (with lymph nodes enlargement and a rash) in June 2006, despite low viral load (630 copies/ml); 86 copies/ml two weeks later; 970 copies/ml at week 4). Viral load increased progressively: 5300 copies/ ml in August 2006 (M2), 17,000 copies/ml in December 2006 (M7), to reach 479,000 copies/ml in September 2007, justifying to start ARV (emtricitabine, tenofovir, lopinavir/ritonavir) ( Fig. 1b and c) . He was HLA-A*01 -A*11, shared HLA-B*07 and HLA-C*07 with the case, and was HLA-B*52, a protective allele, as well as homozygous for DQB1 06 and HLA-C*12 (Supplementary Table 1 ). Finally, he had also a heterozygous CCR5 Δ 32 haplotype. The partner's T cell phenotypic analysis showed no major abnormalities as expected under cART but a slightly increased immune activation and an imbalance towards less naïve and less TfH cells but more differentiated CD4 and CD8 T cells. The NK cell analysis showed in March 2011 characteristics of an HIV progressor, including down-modulation of NKp30 and high frequency of CD57 + NKG2C + NK cells, despite lack of constitutive NK cell activation and of clonal NK-cell population. Poly-functional analysis revealed no major defects, in the presence of K562 targets but no significant antibody-dependant cell cytotoxicity (ADCC) in the presence of Raji cells treated by anti-CD20 mAb, contrasting with the patient. A KIR genotyping analysis revealed that the partner was positive for KIR3DL1 in a context of HLA-Bw4 epitope (Supplementary Table 2 ). Partner was of group A with fewer activating genes, and low diverse repertoire (Supplementary Table 2 ). Contrary to the case patient, the partner had no detectable HIV-1-specific IFN-γ-producing T cells among his PBMC in March 2011, as expected in patients on effective ARV therapy.
Phylogenetic (Fig. 3a) . Any laboratory contamination was excluded since PCR assays were performed several months apart and included two different runs for each partner's sample. Thus, the phylogenic analyses clearly demonstrated that case patient was infected by the same CRF02_AG variant present in his unique sex partner.
Discussion
We report a very rare profile of HIV-1 infection of our case report in which 1) WB was incomplete but consistently reactive during the ten years of follow-up, 2) an ultra-sensitive assay was necessary to detect plasma HIV-1 RNA, 3) HIV-1 specific CD8+ T cells were poly-functional despite at least one pejorative homozygous allele HLA-C*07, 4) a NK response close to that of a healthy individual 5) a robust capacity of producing ADCC in NK cells and 6) neutralizing antibodies were not found.
Both subjects had a heterozygous CCR5Δ32 haplotype, and shared HLA-B*07, C*07, and DQB1 *06.
Phylogenetic analyses demonstrated that the case patient was infected by the same CRF02_AG strain as his only sexual partner. The impossibility to obtain this virus to replicate could be indicative of a reduced fitness; but, as the partner's virus appeared to have a full replicative capacity in 2007, in spite of a heterozygous CCR5Δ32 haplotype, we ruled out the possibility. The virus had to pass two bottlenecks in the partner and in the case patient, as both subjects had a heterozygous CCR5 Δ32 haplotype. The CCR5 Δ32 haplotype deletion in our patient, even heterozygous, could have participated to the observed HIV control, as protective factors could have additive effects (Salgado et al., 2011 , Casado et al., 2010 .
The possibility that the case patient's CD4+ T cells expressed factors restricting HIV-1 replication was also ruled out by in vitro experiments showing his CD4 + T cells were clearly susceptible to various HIV-1 strains, including HIV KON , a primary isolate of the same clade as his own CRF02_AG variant (Fig. 2a) . Thus the different outcomes of the case patient and his partner, despite infection by the same HIV strain, strongly suggest that host/genetic factors rather than viral factors were responsible.
From 2009 to 2015, no major significant difference between our case report and healthy individuals were observed. In contrast, the partner showed some functional markers which are significantly increased in HIV-1 progressors (Gumá Cabrera et al., 2006) . The partner had a massive loss of capacity to producing ADCC in August 2011 (Fig. 4) . Polyfunctional analysis revealed that case report and the partner are only (but strongly) different in their ability to product ADCC (Raji + anti-CD20), but not direct lysis (K562) (Fig. 4) .
HIV-1 WB reactivity has previously been reported in cohorts of elite controllers (Simek et al., 2009; Canouï et al., 2017; Boufassa et al., 2011) . Canouï et al. investigated an extreme HIC subset with undetectable viral load (uHIC) and no viral blips using semi-quantitative HIV-1 WB to detect IgG antibodies against HIV proteins. They found that 10 of the 47 uHICs (21%) lacked at least 1 HIV-specific antibody and were described as having weak IgG responses. Seven of these 10 uHICs lacked either anti-p68 or anti-p34 antibodies. This data further supporting the lack of recent antigenic stimulation in these patients (Canouï et al., 2017) . In the study from Pereyra et al. (2009) , reactivity was detectable to multiple proteins (range 2 to 10), and the majority of individuals (77%) had a complete pattern against all the proteins tested. The most commonly detected antibodies were anti-gp120 and anti-gp160, which were detected in all individuals, followed by anti-p24, -p40 and -gp41, in respectively 98%, 96% and 93% of individuals. The least commonly detected antibodies were those against p18, p31 and p65, which were found in respectively 80%, 84% and 86% of individuals (Pereyra et al., 2009 ). In the previous study, by using an ultrasensitive assay, the results showed that the number of antibodies detected correlated directly with the plasma HIV-1 RNA level, and that full WB reactivity was present in all patients with plasma viral load above 13 copies/mL. In our case report, only one on the eight samples had a VL detectable at 2 copies of HIV-1-RNA/mL of plasma (detection limit b1 copy/mL) by using an ultrasensitive PCR (Fig. 1b) . His sequential patterns of the antibodies to anti-gp160, anti-gp110, anti-gp41, anti-p40, anti-p24, and anti-p18 were in accordance with the previous study, WB remaining incomplete until May 2017 (Fig. 1a) . This report provided extensive longitudinal data on an EC with incomplete WB over a 10-years period. The extremely rare uHICs differ from HICs with blips by significantly lower ultrasensitive plasma HIV-RNA loads and HIV-DNA levels in PBMCs, higher CD4 + T-cell count at enrollment and during follow-up and with lower T-cell activation levels. In our case, the only 2 copies of HIV-1-RNA/mL of plasma detected from 2009 to 2017 (Fig. 1b) and the constantly high CD4 + T cell count above 1000/mm 3 from 2007 until 2017, with, in 2017, CD4+ T-cell count higher than in 2007 (Fig.  1c) , are consistent with the uHIC cohort (Boufassa et al., 2011) . Our patient's blood HIV-1 DNA reservoir appeared smaller than usually observed in ECs and in LTNPs (Fig. 1b) (Boufassa et al., 2011) . This small blood HIV-1 DNA reservoir was accompanied by a very small HIV-1 DNA reservoir in gut-associated lymphoid tissue, as previously reported in several LTNP groups, including untreated patients with primary infection (Avettand-Fenoel et al., 2008) . Half of the uHICs have a protective HLA allele (B*57 or *58 or *B27), weak CD8 + T-cell responses, and very small HIV-DNA reservoir (Canouï et al., 2017) . The case may be one of these extreme controllers. Our case report had poly-functional HIV-1 specific CD8 + T cell responses, coproducing IFN-γ and TNFα were albeit modest and fluctuating. These responses contrasted with his partner's lack of CD8 T cell responses and were markedly higher than observed in HAART-treated non viremic patients but did not differ from those seen elsewhere in chronically viremic patients. Nevertheless they had no significant impact on HIV-1 replication in vitro.
Our case patient was HLA-A*03-A*31, B*07, with C*07 homozygous pejorative alleles (Coloccini et al., 2014) whereas his partner was HLA-B*07-B*52, C*07 heterozygous and C*12 heterozygous. Elite controllers have a variety of genetic backgrounds, although protective HLA as B*27/B*57 alleles are usually over-represented. Interestingly, the case report did not bear any of the classical protective HLA-B*57 and B*27 reported among 45% and 15% of Caucasian HIV controllers respectively versus 6.2% and 6.9%, respectively in the French Caucasian general population; www.allelefrequencies.net. Neither the case report had other protective HLA alleles like HLA-B*13 (Antoni et al., 2013) , B*14 (Antoni et al., 2013; Peterson et al., 2013) , B*51 (Brumme et al., 2011) , B*52 (Antoni et al., 2013) . Our case patient and his partner shared at least one pejorative allele: the case report was homozygous for B*07, the most frequent human allele consistently linked to accelerated disease progression in B-clade, but not in C-clade infection (Kløverpris et al., 2014) . The influence of HLA-B*07 on the control of CRF02_AG variant being unknown to date, this allele cannot be considered as pejorative in this clinical setting. Moreover, the case report was also homozygous for the HLA-C*07 allele (Coloccini et al., 2014) . Transmission of HIV-1 from a patient who developed AIDS to a patient who has maintained undetectable viral loads has already been documented (Bailey et al., 2008) , but unlike our case, either both patients shared the same protective HLA-B*57 allele, or the patient who has maintained undetectable viral loads was HLA-B*57:03 (Buckheit et al., 2012) . Similarly, the four patients described by Mendoza (Mendoza et al., 2012) (without any data about the partners) carried protective HLA class-I alleles, two carried an additional B*57 allele, and none carried pejorative alleles. Moroni et al. (2014) published a case of HIV-1 control in a heterosexual couple lasting N20 years, exploring the genetic background in depth. The woman possessed multiple genetic polymorphisms, including HLA alleles (B*14, B*57, C*06 and C*08.02) and HLA-C single nucleotide polymorphisms (SNPs, rs9264942 C/C and rs67384697 del/del), that have been previously individually associated with spontaneous control of plasma viremia, maintenance of high CD4(+) T cell counts and delayed disease progression.
HLA-B*07 allele does not represent a true pejorative HLA-class I allele such as B35:02, (Martin and Carrington, 2013) , and has been linked to disease progression with rapid seroconversion (Peterson et al., 2013) . Its homozygosity for HLA-B*07-C*07, combined with the absence of a well-known protective HLA-B allele (B27+/B57+/B58+) represents at least a neutral, or a pejorative genetic background (Carrington et al., 1999) . Although some ECs do not possess any protective allele, this might be the first description of an EC homozygous for at least one pejorative allele (HLA-C07 *07) and no protective allele. This is to be compared to the ANRS Visconti study (Samri et al., 2016) in which three of the 14 post-treatment controllers (PTCs) carried one HLA-B*07 allele, two of them carried an additional HLA-B*27 or B*57 allele, and the third carried a non-protective allele. Our findings, together with the Visconti study, clearly show that HLA-B*07 does not rule out PTC or EC status.
Carrying (one or more) same HLA class-I alleles in a previously HIVinfected partner and a person in acute HIV-1 infection might negatively impact virus control following transmission, likely because of CTL escape mutations selected in the previously HIV-infected partner. These patients usually progress rapidly to AIDS and death (Mónaco et al., 2016; Yue et al., 2013) . Nevertheless, despite the fact that our case report and his partner shared HLA-B*07-C*07-DQB1 06, that was obviously not the case here.
HLA-B*52 is known as conferring a strong protective effect during early time points on viral load without significant effect on the longterm control of HIV-1 (Antoni et al., 2013) . When associated with heterozygous deletion for the CCR5Δ D32 haplotype, it could explain the partner's low HIV-1 RNAs observed in acute infection and the fact that our patient has been exposed to low HIV-1 RNAs, albeit a role has not been demonstrated, in the observed outcome.
Early studies reported an increased frequency of HLA-C*04 and HLA-C*07 in HIV-1 infected patients, compared to non-infected controls. HLA-A and HLA-B are downregulated by the HIV nef protein, HLA-C is not. A larger study established the association of HLA-C*04, C*07 and HLA-B*35 with rapid development of AIDS (Zipeto and Beretta, 2012) . HLA-C genotyping revealed that our case report was homozygote for HLA-C*07 and his partner HLA-C*07C*12 (Supplementary Table 2) , suggesting that HLA-C was not associated with the unique HIV profile observed in this patient; we cannot however rule out that HLA-C is differentially expressed at the cell-surface level.
Specific KIR/ligand combinations are associated with the outcome of several viral infectious diseases, and more particularly in HIV-1. The dominant ligands for KIRs have been identified are the C1 and C2 epitopes of HLA-C, that recognized KIR2DL2/2DL3 and KIR2DL1, respectively and HLA-Bw4 that recognized KIR3DL1. Genetic association studies all indicate a role for KIR-HLA interactions in HIV infection, and generally demonstrate an association between disease progression and KIR3DL1 with HLA-Bw4 or/and KIR2DL1 with HLA-C1.
To analyze this interesting point, HLA-class I and KIR genotyping have been performed and analyzed together. This data show that patient and his partner were both HLA-C1/C1 but differed for KIR3DL1 in a context of HLA-Bw4 epitope (Supplementary Table 2 ). The case patient's group was B KIR haplotype, and was positive for KIR3DL1 in a context of HLA-Bw4 epitope, a combination classically-associated with HIV disease progression (Supplementary Table 2 ) (Bashirova et al., 2011) , whereas his partner was of group A, with fewer activating genes, and less diverse repertoire, suggesting that the case patient's NK/T cells could be more functional that those from his partner. Indeed the lack of NK cell abnormality in our patient, compared to his partner (Gumá Cabrera et al., 2006) , together with the more robust ADCC capacity of the case patient's NK cells than of his partner, might suggest a protective efficacy of those cells, as shown in the prophylactic RV144 vaccine trial (Haynes et al., 2012) , and in slow progressors (Wren et al., 2013) .
No neutralizing activity was detected, even towards the highly neutralization-sensitive NL4.3 strain (November 2015). Our results suggest that the extraordinary control of HIV-1 replication was not the result of a particular neutralizing activity. It is not surprising since development of a neutralizing activity requires antigenic stimulation which is only provided by a persistent level of HIV replication and HIV evolution.
The limits of our study were first that, despite we used ultrasensitive PCR for HIV-1 RNA measurement, the threshold varied between 1.1 log and 1.6 log according to the volume available. We could therefore not rule out definitively the possibility of viral blips. Secondly, we cannot exclude the possibility that the variant transmitted to the case patient harbored mutations affecting its replicative properties, as, despite using large volumes of plasma and PBMC, we could not isolate the case patient's whole virus. When the case patient was referred in November 2007, the partner was already treated with ARV since September 2007; for ethical reasons we did not withdraw partner's treatment to try to sequence the virus and to study the replicative capacity. Thirdly, we assessed NK cell potential by using rituximab plus Raji, but we were not able to assess the potential of serum antibodies from patients to perform ADCC function, or at least provide antibody isotypes and HIV recognition data, as there was not any plasma or serum available from our patient, and the partner moved to the provinces and was lost-to-follow-up.
A fragment of the integrase coding region (pol-IN) was amplified by PCR, but all subsequent amplification attempts, with targets including highly conserved regions of the env gene (gp41), were all negative. Phylogenetic analysis was thus performed based only on the pol-IN fragment. We suggest that such failure is due to the low virus load in the patient.
In conclusion, we described an extremely prolonged and spontaneous almost complete control of HIV-1 replication in the blood and different tissues despite the lack of protective alleles. Our study may imply that the genetic background of the exposed person, the genetic background of the source, and the viral strain could interact with each other to obtain an elite controller. This case which might belong to the extremely rare subset of extreme HIV controllers with undetectable virus loads, might be taken as a model and as a creative step, in a positive direction, for future control of HIV disease (Autran et al., 2011 , Autran, 2015 .
Supplementary data to this article can be found online at https://doi. org/10.1016/j.ebiom.2017.12.003. 
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